{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:42:11Z","timestamp":1792608131800,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate the Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumour Association Prediction (DELTA-P) score in a prospective cohort of patients with newly diagnosed LEMS to assess the clinical validity of this tool in a real-world setting. Clinical features from 87 patients with LEMS, occurring within three months from disease onset, were collated to produce a DELTA-P score for each patient. Lung cancer was detected in 44\/87 (51%) LEMS patients. Weight loss\u2009\u2265\u20095%, tobacco use at LEMS onset and age at onset\u2009\u2265\u200950\u00a0years were independent predictors for the development of small-cell lung cancer (SCLC) in LEMS patients in multivariable analysis. Median DELTA-P scores were significantly higher in SCLC-LEMS patients (3.5, 95% CI 3 to 4) compared to non-tumour-LEMS (2, 95% CI 1 to 2) (P\u2009&lt;\u20090.0001). Higher DELTA-P scores increased the risk of SCLC stepwise (score 0\u2009=\u20090%, 1\u2009=\u200918.8%, 2\u2009=\u200945%, 3\u2009=\u200955.5%, 4\u2009=\u200985.7%, 5\u2009=\u200987.5%, 6\u2009=\u2009100%). The area under the curve of the receiver operating curve was 82.5% (95% CI 73.9% to 91%). The DELTA-P cancer prediction score, calculated at the time of LEMS diagnosis, is an effective tool for cancer screening in an independent, prospective study setting.<\/jats:p>","DOI":"10.1038\/s41598-020-67571-9","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T10:03:01Z","timestamp":1593424981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort"],"prefix":"10.1038","volume":"10","author":[{"given":"Paul","family":"Maddison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander F.","family":"Lipka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gozzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girija","family":"Sadalage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"67571_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/brain\/111.3.577","volume":"111","author":"JH O\u2019Neill","year":"1988","unstructured":"O\u2019Neill, J. H., Murray, N. M. & Newsom-Davis, J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111, 577\u2013596 (1988).","journal-title":"Brain"},{"key":"67571_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1113\/jphysiol.1987.sp016698","volume":"390","author":"B Lang","year":"1987","unstructured":"Lang, B., Newsom-Davis, J., Peers, C., Prior, C. & Wray, D. W. The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse. J. Physiol. 390, 257\u2013270 (1987).","journal-title":"J. Physiol."},{"key":"67571_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","volume":"147","author":"M Motomura","year":"1997","unstructured":"Motomura, M. et al. Incidence of serum anti-P\/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J. Neurol. Sci. 147, 35\u201342 (1997).","journal-title":"J. Neurol. Sci."},{"key":"67571_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0165-5728(00)00431-8","volume":"113","author":"M Benatar","year":"2001","unstructured":"Benatar, M. et al. Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. J. Neuroimmunol. 113, 153\u2013162 (2001).","journal-title":"J. Neuroimmunol."},{"key":"67571_CR5","doi-asserted-by":"publisher","first-page":"e89426","DOI":"10.1371\/journal.pone.0089426","volume":"9","author":"A Khakwani","year":"2014","unstructured":"Khakwani, A. et al. Small-cell lung cancer in England: trends in survival and chemotherapy using the National Lung Cancer Audit. PLoS ONE 9, e89426 (2014).","journal-title":"PLoS ONE"},{"key":"67571_CR6","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(11)60165-7","volume":"378","author":"JP van Meerbeeck","year":"2011","unstructured":"van Meerbeeck, J. P., Fennell, D. A. & De Ruysscher, D. K. Small-cell lung cancer. Lancet 378, 1741\u20131755 (2011).","journal-title":"Lancet"},{"key":"67571_CR7","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1200\/JCO.2008.17.5133","volume":"26","author":"MJ Titulaer","year":"2008","unstructured":"Titulaer, M. J. et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J. Clin. Oncol. 26, 4276\u20134281 (2008).","journal-title":"J. Clin. Oncol."},{"key":"67571_CR8","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","volume":"29","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer, M. J. et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J. Clin. Oncol. 29, 902\u2013908 (2011).","journal-title":"J. Clin. Oncol."},{"key":"67571_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1017\/S0317167100002729","volume":"30","author":"S Gill","year":"2003","unstructured":"Gill, S., Murray, N., Dalmau, J. & Thiessen, B. Paraneoplastic sensory neuronopathy and spontaneous regression of small cell lung cancer. Can. J. Neurol. Sci. 30, 269\u2013271 (2003).","journal-title":"Can. J. Neurol. Sci."},{"key":"67571_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.01.2009.1486","author":"E Mawhinney","year":"2010","unstructured":"Mawhinney, E., Gray, O. M., McVerry, F. & McDonnell, G. V. Paraneoplastic sensorimotor neuropathy associated with regression of small cell lung carcinoma. BMJ Case Rep https:\/\/doi.org\/10.1136\/bcr.01.2009.1486 (2010).","journal-title":"BMJ Case Rep"},{"key":"67571_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5","volume":"19","author":"DG Altman","year":"2000","unstructured":"Altman, D. G. & Royston, P. What do we mean by validating a prognostic model?. Stat. Med. 19, 453\u2013473 (2000).","journal-title":"Stat. Med."},{"key":"67571_CR12","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.ahj.2004.02.014","volume":"148","author":"AT Yan","year":"2004","unstructured":"Yan, A. T. et al. Clinical trial\u2013derived risk model may not generalize to real-world patients with acute coronary syndrome. Am. Heart J. 148, 1020\u20131027 (2004).","journal-title":"Am. Heart J."},{"key":"67571_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/sim.4780030207","volume":"3","author":"FE Harrell","year":"1984","unstructured":"Harrell, F. E., Lee, K. L., Califf, R. M., Pryor, D. B. & Rosati, R. A. Regression modelling strategies for improved prognostic modelling. Stat. Med. 3, 143\u2013152 (1984).","journal-title":"Stat. Med."},{"key":"67571_CR14","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","volume":"10","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer, M. J., Lang, B. & Verschuuren, J. J. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 10, 1098\u20131107 (2011).","journal-title":"Lancet Neurol."},{"key":"67571_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/mus.20389","volume":"32","author":"SJ Oh","year":"2005","unstructured":"Oh, S. J., Kurokawa, K., Claussen, G. C. & Ryan, H. F. Jr. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 32, 515\u2013520 (2005).","journal-title":"Muscle Nerve"},{"key":"67571_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/mus.24745","volume":"52","author":"FY Chiou-Tan","year":"2015","unstructured":"Chiou-Tan, F. Y. & Gilchrist, J. M. Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: Review of recent literature. Muscle Nerve 52, 455\u2013462 (2015).","journal-title":"Muscle Nerve"},{"key":"67571_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1148\/radiology.148.3.6878708","volume":"148","author":"JA Hanley","year":"1983","unstructured":"Hanley, J. A. & McNeil, B. J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148, 839\u2013843 (1983).","journal-title":"Radiology"},{"key":"67571_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/0272989X8400400203","volume":"4","author":"BJ McNeil","year":"1984","unstructured":"McNeil, B. J. & Hanley, J. A. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med. Decis. Making 4, 137\u2013150 (1984).","journal-title":"Med. Decis. Making"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67571-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67571-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67571-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:46:11Z","timestamp":1670330771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67571-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["67571"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-67571-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"9 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors Maddison, Lipka, Gozzard, Sadalage and Ambrose declare no competing interests. Dr Lang is a co-applicant and receives royalties on patent application WO\/2010\/046716 entitled 'Neurological Autoimmune Disorders'. The patent has been licensed to Euroimmun AG for the development of assays for LGI1 and other VGKC-complex antibodies.Professor Verschuuren reports involvement in a National Institutes of Health-sponsored thymectomy trial (ClinicalTrials.gov, number NCT00294658), reports a FP7 European MG grant (602420); and is a consultant for Alexion Pharmaceuticals and arGEN-X.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10546"}}